Responses Seen With Anti-PD-1 Antibody in Anaplastic Thyroid Cancer Cohort

Lori J. Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, discussed the findings for a small cohort of patients with anaplastic thyroid cancer treated with an anti-PD-1 antibody.

Overall, 42 patients were enrolled and received spartalizumab (PDR001). Besides dabrafenib (Tafinlar) and trametinib (Mekinist), this patient population has very limited treatment options. However, Wirth reported that these patients had a 22% response rate with spartalizumab.